UCLA's Jonsson Comprehensive Cancer Center : JCCC Member Directory

Howard Reber, M.D.

Specialty:

Surgery General

General Information:

Gender:	Male
Language(s):	English

Affiliation(s):

Distinguished Professor, Department of Surgery

Director, Department of Medicine, Hematology/Oncology, Pancreatic Cancer Program

Physician, General Surgery, Pancreatic Disease

Member, JCCC Community

Hospital Affiliation(s):

Ronald Reagan UCLA Medical Center

Education:

Residency:	Surgery, Hospital of the University of Pennsylvania, 1964 - 1970
Internship:	Rotating (Internship), Hospital of the University of Pennsylvania, 1963 - 1964
Medical Degree:	M.D., University of Pennsylvania School of Medicine, 1963

Certification(s):

Medical Board Certification(s):	Surgery, American Board of Surgery, 1971

Contact Information:

Surgery:	(310) 794-7788 Patient appointments
General Surgery:	(310) 794-7788 Information, referral, and outpatient clinic appointments - Westwood (310) 319-4080 Information, referral, and outpatient clinic appointments - Santa Monica
Pancreatic Cancer Program:	(310) 794-7788 Information and referral
Pancreatic Disease:	(310) 825-1597 Information and referral
Email:	hreber@mednet.ucla.edu

Practice Information:

Clinical Interest(s):	Gastrointestinal Hepatobiliary Pancreas

Scientific Interest(s):

Dr. Howard Reber's research focuses on acute and chronic pancreatitis, as well as pancreatic cancer.

Selected Cancer-Related Publications:

Kazanjian KK, Hines OJ, Duffy JP, Yoon DY, Cortina G, Reber HA. Improved survival following pancreaticoduodenectomy to treat adenocarcinoma of the pancreas: the influence of operative blood loss. Arch Surg. 2008 Dec;143(12):1166-71.

Bhargava S, Hotz B, Hines OJ, Reber HA, Buhr HJ, Hotz HG. Suramin inhibits not only tumor growth and metastasis but also angiogenesis in experimental pancreatic cancer. J Gastrointest Surg. 2007; 11:171-178.

Buchler P, Reber HA, Roth MM, Shiroishi M, Friess, Hines OJ. Target therapy using a small molecule inhibitor against angiogenic receptors in pancreatic cancer. Neoplasia. 2007; 9:119-127.

Funahashi H, Satake M, Dawson D, Huynh NA, Reber HA, Hines OJ, Eibl G. Delayed progression of pancreatic intraepithelial neoplasia in a conditional KrasG12D mouse model by a selective cyclooxygenase-2 inhibitor. Cancer Res. 2007; 67:7068-7071.

Tomlinson JS, Jain S, Bentrem DJ, Sekeris EG, Maggard MA, Hines OJ, Reber HA, Ko CY. Accuracy of staging node negative pancreas cancer: a potential quality measure. Arch Surg. 2007; 142:767-774.